Vitae Pharmaceuticals Company Profile (NASDAQ:VTAE)

About Vitae Pharmaceuticals

Vitae Pharmaceuticals logoVitae Pharmaceuticals, Inc. is a biotechnology company. The Company is focused on discovering and developing small molecule drugs for diseases. It is engaged in developing a portfolio of product candidates through Contour, its structure-based drug discovery platform. The Company's product candidates include VTP- 43742 for the treatment of psoriasis, as well as multiple other autoimmune disorders. The Company completed approximately two Phase I studies with VTP-43742. Its VTP-38543, a second product candidate is in a Phase IIa proof-of-concept clinical trial for the treatment of atopic dermatitis. Its VTP-36951 is for the treatment and prevention of Alzheimer's disease, or Alzheimer's. VTP-43742, the Company's wholly owned clinical candidate in an on-going Phase IIa proof-of-concept trial in psoriasis, is an orally active small molecule inhibitor of Retinoic acid-receptor (RAR)-Related Orphan Receptor gamma-t (RORgt) activity for the treatment of various autoimmune disorders.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: VTAE
  • CUSIP:
Key Metrics:
  • Previous Close: $20.96
  • 50 Day Moving Average: $11.92
  • 200 Day Moving Average: $9.51
  • 52-Week Range: $4.08 - $20.97
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -11.02
  • P/E Growth: 0.00
  • Market Cap: $603.64M
  • Outstanding Shares: 28,841,000
  • Beta: 1.08
Profitability:
  • Net Margins: -13,954.35%
  • Return on Equity: -65.51%
  • Return on Assets: -59.63%
Debt:
  • Current Ratio: 12.83%
  • Quick Ratio: 12.83%
Additional Links:
Companies Related to Vitae Pharmaceuticals:

Analyst Ratings

Consensus Ratings for Vitae Pharmaceuticals (NASDAQ:VTAE) (?)
Ratings Breakdown: 6 Hold Ratings
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: $22.00 (5.11% upside)

Analysts' Ratings History for Vitae Pharmaceuticals (NASDAQ:VTAE)
Show:
DateFirmActionRatingPrice TargetDetails
9/20/2016Piper Jaffray Cos.DowngradeOverweight -> NeutralView Rating Details
9/15/2016BMO Capital MarketsDowngradeOutperform -> Market Perform$17.00 -> $21.00View Rating Details
9/14/2016WedbushDowngradeOutperform -> Neutral$21.00 -> $23.00View Rating Details
9/14/2016Stifel NicolausDowngradeBuy -> Hold$21.00View Rating Details
9/11/2016Wells Fargo & Co.DowngradeOutperform -> Market PerformView Rating Details
8/4/2016JMP SecuritiesDowngradeOutperform -> Market PerformView Rating Details
(Data available from 9/29/2014 forward)

Earnings

Earnings History for Vitae Pharmaceuticals (NASDAQ:VTAE)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/3/2016        
8/3/2016Q2($0.41)($0.36)ViewListenView Earnings Details
5/10/2016Q1($0.51)($0.44)$0.05 millionViewListenView Earnings Details
3/3/2016Q415($0.62)($0.52)$0.14 million$0.09 millionViewListenView Earnings Details
11/5/2015Q315($0.48)($0.60)$0.18 million$0.18 millionViewListenView Earnings Details
8/4/2015Q215($0.45)($0.45)$0.09 million$0.16 millionViewListenView Earnings Details
5/13/2015Q115($0.33)($0.47)$0.08 millionViewListenView Earnings Details
3/31/2015Q414($0.45)($0.40)$0.19 million$0.16 millionViewListenView Earnings Details
11/12/2014Q3($0.13)($1.03)$6.39 million$6.18 millionViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Vitae Pharmaceuticals (NASDAQ:VTAE)
Current Year EPS Consensus Estimate: $-1.66 EPS
Next Year EPS Consensus Estimate: $-1.9 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.39)($0.39)($0.39)
Q2 20161($0.35)($0.35)($0.35)
Q3 20161($0.35)($0.35)($0.35)
Q4 20161($0.34)($0.34)($0.34)
Q1 20171($0.34)($0.34)($0.34)
Q2 20171($0.34)($0.34)($0.34)
Q3 20171($0.32)($0.32)($0.32)
Q4 20171($0.29)($0.29)($0.29)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Vitae Pharmaceuticals (NASDAQ:VTAE)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Vitae Pharmaceuticals (NASDAQ:VTAE)
Insider Ownership Percentage: 14.80%
Institutional Ownership Percentage: 72.93%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/14/2016Adage Capital Partners Gp, L.LMajor ShareholderSell1,025,000$20.85$21,371,250.00View SEC Filing  
9/14/2016Jeffrey S HatfieldCEOSell50,000$20.81$1,040,500.00View SEC Filing  
3/21/2016Donald J Hayden JrDirectorSell16,130$7.42$119,684.60View SEC Filing  
12/29/2015Donald J. Hayden, Jr.DirectorSell16,130$18.00$290,340.00View SEC Filing  
12/23/2015Jeffrey S. HatfieldCEOSell22,524$17.00$382,908.00View SEC Filing  
9/21/2015Donald J. Hayden, Jr.DirectorSell16,130$17.00$274,210.00View SEC Filing  
9/29/2014Peter BarrettDirectorBuy37,500$8.00$300,000.00View SEC Filing  
9/29/2014Venrock Management Iii LlcMajor ShareholderBuy772,333$8.00$6,178,664.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Vitae Pharmaceuticals (NASDAQ:VTAE)
DateHeadline
News IconInvestor News: Buyout of Vitae Pharmaceuticals Inc (NASDAQ:VTAE) under Investigation (NASDAQ:VTAE)
www.groundreport.com - September 28 at 7:47 PM
News IconTime To Put On The Watch List? - Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), Nektar Therapeutics (NASDAQ:NKTR) - The Voice Registrar (NASDAQ:VTAE)
voiceregistrar.com - September 28 at 7:27 AM
News IconInvestor News: Buyout of Vitae Pharmaceuticals Inc (NASDAQ:VTAE ... - GroundReport (NASDAQ:VTAE)
www.groundreport.com - September 28 at 7:27 AM
prnewswire.com logoVITAE SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Announces ... - PR Newswire (press release) (NASDAQ:VTAE)
www.prnewswire.com - September 25 at 6:58 AM
finance.yahoo.com logoVITAE SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Announces the Investigation of Vitae Pharmaceuticals, … (NASDAQ:VTAE)
finance.yahoo.com - September 24 at 6:56 AM
News IconHC Stocks Outlines! Vitae Pharmaceuticals Inc (VTAE), Great Basin ... - share market updates (press release) (NASDAQ:VTAE)
sharemarketupdates.com - September 23 at 7:22 PM
thestreet.com logoAllergan's Vitae buy could spark more interest in Kadmon (NASDAQ:VTAE)
www.thestreet.com - September 23 at 6:49 AM
News IconHC Stocks Outlines! Baxter International Inc (BAX), Vitae ... - share market updates (press release) (NASDAQ:VTAE)
sharemarketupdates.com - September 21 at 11:53 AM
News IconHC Stocks Indications! Apricus Biosciences Inc (APRI), Vitae Pharmaceuticals Inc (NASDAQ:VTAE) - share market updates (press release) (NASDAQ:VTAE)
sharemarketupdates.com - September 21 at 11:53 AM
benzinga.com logoAllergan's Tobira Acquisition Represents The Highest Premium Ever Paid In Biopharma - Benzinga (NASDAQ:VTAE)
www.benzinga.com - September 21 at 11:53 AM
4-traders.com logoAcquisition of Vitae Pharmaceuticals Inc (NASDAQ:VTAE) Under Investigation for Investors (NASDAQ:VTAE)
www.4-traders.com - September 19 at 7:55 PM
News IconHC Stocks Growth= Apricus Biosciences Inc (NASDAQ:APRI), Vitae ... - share market updates (press release) (NASDAQ:VTAE)
sharemarketupdates.com - September 16 at 7:43 PM
capitalcube.com logoVitae Pharmaceuticals, Inc. – Value Analysis (NASDAQ:VTAE) : September 16, 2016 (NASDAQ:VTAE)
www.capitalcube.com - September 16 at 7:43 PM
News IconWhat are Analyst Opinions for Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE) - Newburg Press (NASDAQ:VTAE)
newburghpress.com - September 16 at 11:41 AM
streetinsider.com logoAllergan (AGN) to Acquire Vitae Pharmaceuticals (VTAE) for $639M - StreetInsider.com (NASDAQ:VTAE)
www.streetinsider.com - September 16 at 11:41 AM
News IconTrading the Biotech News: Medivation, Inc. (NASDAQ:MDVN), Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE) - The Voice Registrar (NASDAQ:VTAE)
voiceregistrar.com - September 16 at 11:41 AM
News IconBlog Coverage Allergan Boosts its RandD Expenditure and Pours 639m Dollars in the New Merger (NASDAQ:VTAE)
news.investornetwork.com - September 16 at 11:41 AM
News IconINVESTOR ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Vitae Pharmaceuticals, Inc. And Encourages ... (NASDAQ:VTAE)
ih.advfn.com - September 15 at 8:08 PM
finance.yahoo.com logoINVESTOR ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Vitae Pharmaceuticals, Inc. And Encourages Shareholders To Contact The Firm For Additional Information (NASDAQ:VTAE)
finance.yahoo.com - September 15 at 8:08 PM
News IconSHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Regarding the Fairness of the Sale of Vitae Pharmaceutica... (NASDAQ:VTAE)
ih.advfn.com - September 15 at 11:48 AM
News IconVitae Pharmaceuticals Inc (NASDAQ:VTAE): Believe Or Not, That’s How Our Subscribers Doubled Money In Just 10-Week (NASDAQ:VTAE)
www.marketnewscall.com - September 15 at 11:48 AM
rttnews.com logoVitae Pharmaceuticals Inc. (VTAE) Vaulted To A New High After Merger (NASDAQ:VTAE)
www.rttnews.com - September 15 at 11:48 AM
capitalcube.com logoVitae Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : VTAE-US : September 15, 2016 (NASDAQ:VTAE)
www.capitalcube.com - September 15 at 11:48 AM
finance.yahoo.com logoAllergan to Buy Vitae Pharma to Boost Dermatology Suite (NASDAQ:VTAE)
finance.yahoo.com - September 15 at 11:48 AM
thestreet.com logoVitae Pharmaceuticals (VTAE) Stock Downgraded at BMO Capital (NASDAQ:VTAE)
www.thestreet.com - September 15 at 11:48 AM
finance.yahoo.com logoCompany News for September 15, 2016 (NASDAQ:VTAE)
finance.yahoo.com - September 15 at 11:48 AM
finance.yahoo.com logoSHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Regarding the Fairness of the Sale of Vitae Pharmaceuticals, Inc. to Allergan plc for $21.00 Per Share (NASDAQ:VTAE)
finance.yahoo.com - September 15 at 11:48 AM
capitalcube.com logoETF’s with exposure to Vitae Pharmaceuticals, Inc. : September 15, 2016 (NASDAQ:VTAE)
www.capitalcube.com - September 15 at 11:48 AM
prnewswire.com logoHarwood Feffer LLP Announces Investigation of Vitae Pharmaceuticals, Inc. - PR Newswire (press release) (NASDAQ:VTAE)
www.prnewswire.com - September 14 at 8:14 PM
streetinsider.com logoUnusual 11 Mid-Day Movers 9/14: (VTAE) (ACST) (SRPT) Higher; (LFVN) (RFIL) (RLGT) Lower - StreetInsider.com (NASDAQ:VTAE)
www.streetinsider.com - September 14 at 8:14 PM
marketwatch.com logoAllergan to acquire Vitae Pharma in an all-cash deal valued at about $639 million - MarketWatch (NASDAQ:VTAE)
www.marketwatch.com - September 14 at 8:14 PM
schaeffersresearch.com logoDow Jones Industrial Average Futures Signal Rebound - Schaeffers Research (blog) (NASDAQ:VTAE)
www.schaeffersresearch.com - September 14 at 12:25 PM
News IconVitae Pharmaceuticals Inc (NASDAQ:VTAE): Believe Or Not, That's How Our Subscribers Doubled Money In Just 10 ... - Market News Call (NASDAQ:VTAE)
www.marketnewscall.com - September 14 at 12:25 PM
News IconStock Gapping Higher Before the Bell: Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE) - Post News (NASDAQ:VTAE)
www.kentuckypostnews.com - September 14 at 12:25 PM
streetinsider.com logoNotable Mergers and Acquisitions 9/14: (MON) (AEP)/(BX) (AGN)/(VTAE) (SYK) - StreetInsider.com (NASDAQ:VTAE)
www.streetinsider.com - September 14 at 12:25 PM
investorplace.com logoAllergan plc Ordinary Shares (AGN) Up on $639M Buyout of Vitae Pharmaceuticals Inc (VTAE) - Investorplace.com (NASDAQ:VTAE)
investorplace.com - September 14 at 12:25 PM
finance.yahoo.com logoVITAE PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout (NASDAQ:VTAE)
finance.yahoo.com - September 14 at 12:25 PM
fool.com logoHere's Why Shares of Vitae Pharmaceuticals Inc Are Skyrocketing Today (NASDAQ:VTAE)
www.fool.com - September 14 at 12:25 PM
insidermonkey.com logoFive Stocks Trading Higher Amid Positive News (NASDAQ:VTAE)
www.insidermonkey.com - September 14 at 12:25 PM
cnbc.com logoAllergan to buy US drug developer Vitae Pharmaceuticals for $639 million (NASDAQ:VTAE)
www.cnbc.com - September 14 at 12:25 PM
investorplace.com logoAllergan plc Ordinary Shares (AGN) Up on $639M Buyout of Vitae Pharmaceuticals Inc (VTAE) (NASDAQ:VTAE)
investorplace.com - September 14 at 11:00 AM
News IconWhat are Analysts Expecting for Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE) Earnings? - Frisco Fastball (NASDAQ:VTAE)
friscofastball.com - September 9 at 7:39 PM
News IconThe Sell-side Consensus is in on Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE); Earnings & Target Updates - National Daily Press (NASDAQ:VTAE)
www.nationaldailypress.com - September 9 at 7:39 PM
News IconShares Higher in Today's Session: Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE) - Post News (NASDAQ:VTAE)
www.kentuckypostnews.com - September 9 at 6:40 AM
News IconStock Showing Gains in Afternoon Trading: Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE) - National Daily Press (NASDAQ:VTAE)
www.nationaldailypress.com - September 9 at 6:40 AM
News IconTrading Update – Increased Volatility Noted on Shares of Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE) - National Daily Press (NASDAQ:VTAE)
www.nationaldailypress.com - September 8 at 7:41 PM
News IconStock Struggling for the Quarter: Vitae Pharmaceuticals, Inc ... - Post News (NASDAQ:VTAE)
www.kentuckypostnews.com - September 4 at 6:43 AM
globenewswire.com logoVitae Pharmaceuticals to Present at Wells Fargo Healthcare Conference - GlobeNewswire (press release) (NASDAQ:VTAE)
www.globenewswire.com - September 1 at 8:02 PM
publicnow.com logoVitae Pharmaceuticals to Present at Wells Fargo Healthcare Conference (NASDAQ:VTAE)
www.publicnow.com - September 1 at 8:02 PM
News IconShares Down for the Quarter: Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE) - Post News (NASDAQ:VTAE)
www.kentuckypostnews.com - August 28 at 6:46 AM

Social

Vitae Pharmaceuticals (NASDAQ:VTAE) Chart for Thursday, September, 29, 2016


Last Updated on 9/29/2016 by MarketBeat.com Staff